Dipyridamole: profile and news

Anti-Platelet Use Reduces Stroke Severity and Improves Outcomes in ... Feb 20, 2006
...alone, 11 were taking aspirin with clopidogrel, 1 was taking clopidogrel with warfarin, 5 were taking aspirin with extended release dipyridamole, and 1 was ... - DG News

Secondary Stroke Prevention Guidelines Call for Upgrade of TIA ... Feb 21, 2006
For reduction in risk of recurrent stroke, antiplatelet therapy with aspirin alone, aspirin plus extended release dipyridamole or clopidogrel are all options ... - Medscape (subscription)

CombinatoRx Drug Candidate CRx-102 Demonstrates Positive Phase 2 ... Jan 30, 2006
AUSCAN scale. CRx-102 was dosed in this trial using 3mg of prednisolone and two different doses of dipyridamole. Patients received ... - Genetic Engineering News,

Dipyridamole, ASA and warding off stroke Oct 26, 2005
...comments on the recent decision by the influential UK National Institute for Heath and Clinical Excellence (NICE) to recommend that dipyridamole be recommended ... - Medical News Today (press release),

PET and PET-CT: Expanding the Scope of Cardiovascular Imaging Aug 23, 2005
During pharmacologic stress with dipyridamole or adenosine stress, coronary vessels respond with an endothelial-mediated and smooth muscle-mediated vasodilation ... - Medscape (subscription)

THE FAMILY DOCTOR Aug 23, 2005
To decrease the risk of blood clots, even with a higher number of platelets, you may want to try aspirin or dipyridamole, but this needs to be balanced against ... - Newsday,

Review: Dipyridamole Given With or Without Aspirin Reduces ... Jul 24, 2005
Dipyridamole for preventing recurrent ischemie stroke and other vascular events: a metaanalysis of individual patient data from randomized controlled trials. ... - RedNova.com

Value of absence of a transient myocardial perfusion defect during ... Jul 15, 2005
Thirty-eight patients received adenosine infusion of 140 mug/kg/min for 6 min. Six patients received dipyridamole infusion of 0.56 mg/kg over 4 min. ... - HeartZine

Noninvasive Diagnosis of Coronary Artery Disease in Patients With ... Jul 9, 2005
...(17) determined the accuracy of intravenous dipyridamole myocardial thallium scintigraphy in 59 middle-aged diabetic patients with suspected CAD. ... - RedNova.com <**results**>

The Many Ways to Myocardial Perfusion Imaging Jun 12, 2005
...reserve implies that a second set of images is acquired after the intravenous administration of a pharmacological stress agent such as dipyridamole or adenosine ... - RedNova.com

Assessment of Myocardial Viability in Chronic Ischemic Heart ... Jun 12, 2005
Dobutamine and dipyridamole are generally used as stressors. ... The infusion of high dosages of dipyridamole and dobutamine may induce ischemia. ... - RedNova.com,

NICE Recommends Aggrenox (dipyridamol) as First Line Treatment for ... Jun 6, 2005
Clinical Excellence (NICE) in England and Wales has recommended the use of Aggrenox®/ Asasantin® retard, modified release dipyridamole with acetylsalicylic ... - PharmaLive.com (press release),

Brain Attack A Look at Stroke Prevention and Treatment May 13, 2005
Antiplatelet drugs, such as aspirin, Plavix (clopidogrel), Ticlid (ticlopidine), and Aggrenox (aspirin and dipyridamole), prevent clotting by decreasing ... - FDA.gov

UK Centres Lead Trial to Evaluate Modern Stent Technologies Over ... Apr 28, 2005
2. National Institute for Clinical Excellence Final Appraisal Determination Clipidogrel and modified-release dipyridamole in the prevention of occlusive ... - mysan.de (Pressemitteilung),

UK Centres Lead Trial to Evaluate Modern Stent Technologies Over ... 28 Apr 2005
2. National Institute for Clinical Excellence Final Appraisal Determination Clipidogrel and modified-release dipyridamole in the prevention of occlusive ... - mysan.de (Pressemitteilung),

Oral Antiplatelet Therapy Feb 15, 2005
First, the use of combined aspirin and extended-release dipyridamole (ASA-ERDP) in patients with concomitant symptomatic CAD is described as questionable, due ... - Journal of American Medical Association (subscription),

Oral Antiplatelet Therapy—Reply Feb 15, 2005
...this in principle, the evidence for ASA-ERDP comes from a single large trial (ESPS-2). 5 Furthermore, an overview of short-acting dipyridamole suggests that ... - Journal of American Medical Association (subscription),

Assessment of minimally invasive direct coronary artery bypass ... Mar 4, 2005
...flow measurements with retrospective gating were performed in the internal thoracic artery grafts at rest and after stress induction with dipyridamole (0.57 mg ... - The Journal of Thoracic and Cardiovascular Surgery

Stroke Prevention Guidelines From the National Stroke Association Feb 22, 2005
If your doctor prescribes aspirin, warfarin, ticlopidine, clopidogrel, dipyridamole, or other medicine for circulation problems, take it exactly as prescribed. ... - Yahoo News (press release)

Other information

Indication
For as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina

Pharmacology
Dipyridamole, a non-nitrate coronary vasodilator that also inhibits platelet aggregation, is combined with other anticoagulant drugs, such as warfarin, to prevent thrombosis in patients with valvular or vascular disorders. Dipyridamole is also used in myocardial perfusion imaging, as an antiplatelet agent, and in combination with aspirin for stroke prophylaxis.

Mechanism Of Action
Dipyridamole likely inhibits both adenosine deaminase and phosphodiesterase, preventing the degradation of cAMP, an inhibitor of platelet function. This elevation in cAMP blocks the release of arachidonic acid from membrane phospholipids and reduces thromboxane A2 activity. Dipyridamole also directly stimulates the release of prostacyclin, which induces adenylate cyclase activity, thereby raising the intraplatelet concentration of cAMP and further inhibiting platelet aggregation.

Drug Category
Vasodilator Agents; Vasodilator Agents; ATC:B01AC07

Brand Names/Synonyms
Aggrenox; Agilease; Anginal; Apo-Dipyridamole Fc; Apo-Dipyridamole Sc; Apricor; Cardioflux; Cardoxil; Cardoxin; Chilcolan; Cleridium; Cleridium 150; Coribon; Coridil; Coronarine; Corosan; Coroxin; Curantyl; Dipiridamol; Dipyridamine; Dipyridamol; Dipyridamole; Dipyridamole, Pharma; Dipyridan; Dipyudamine; Dypyridamol; Gulliostin; Iv Persantine; Justpertin; Kurantil; Natyl; Novo-Dipiradol; Peridamol; Permiltin; Persantin; Persantine; Piroan; Prandiol; Prandiol 75; Protangix; RA 8; RA-8; Stenocardil; Stenocardiol; Stimolcardio; Usaf Ge-12

Dosage Forms
tablets

Absorption
70%

Interactions
Interactions for Dipyridamole:

No pharmacokinetic drug-drug interaction studies were conducted with PERSANTINE® (dipyridamole USP) Tablets. The following information was obtained from the literature.

Adenosine: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of adenosine. Adjustment of adenosine dosage may be necessary.

Cholinesterase Inhibitors: Dipyridamole may counteract the anticholinesterase effect of cholinesterase inhibitors, thereby potentially aggravating myasthenia gravis.

Chemical IUPAC Name
2-[[3-[bis(2-hydroxyethyl)amino]-5,10-bis(1-piperidyl)-2,4,7,9-tetrazabicyclo[4.4.0]deca-2,4,7,9,11-pentaen-8-yl]-(2-hydroxyethyl)amino]ethanol

Chemical Formula
C24H40N8O4

Half Life
40 minutes

Drug Type
Approved Drug

# Accession No
APRD00360

CAS Registry Number
58-32-2